HK1198126A1 - Chemokine immunoglobulin fusion polypeptides, compositions, method of making and use thereof - Google Patents

Chemokine immunoglobulin fusion polypeptides, compositions, method of making and use thereof

Info

Publication number
HK1198126A1
HK1198126A1 HK14111652.0A HK14111652A HK1198126A1 HK 1198126 A1 HK1198126 A1 HK 1198126A1 HK 14111652 A HK14111652 A HK 14111652A HK 1198126 A1 HK1198126 A1 HK 1198126A1
Authority
HK
Hong Kong
Prior art keywords
chemokine
compositions
making
fusion polypeptides
immunoglobulin fusion
Prior art date
Application number
HK14111652.0A
Other languages
English (en)
Chinese (zh)
Inventor
．利拉德 詹姆斯．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1198126A1 publication Critical patent/HK1198126A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HK14111652.0A 2011-06-01 2014-11-18 Chemokine immunoglobulin fusion polypeptides, compositions, method of making and use thereof HK1198126A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161492260P 2011-06-01 2011-06-01
PCT/US2012/039550 WO2012166588A2 (en) 2011-06-01 2012-05-25 Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

Publications (1)

Publication Number Publication Date
HK1198126A1 true HK1198126A1 (en) 2015-03-13

Family

ID=47260212

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14111652.0A HK1198126A1 (en) 2011-06-01 2014-11-18 Chemokine immunoglobulin fusion polypeptides, compositions, method of making and use thereof

Country Status (7)

Country Link
US (2) US8541564B2 (xx)
EP (1) EP2714065A4 (xx)
JP (1) JP2014518632A (xx)
CN (2) CN103857406B (xx)
AU (1) AU2012262491A1 (xx)
HK (1) HK1198126A1 (xx)
WO (1) WO2012166588A2 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9352000B2 (en) 2010-05-05 2016-05-31 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
US9717777B2 (en) 2010-05-05 2017-08-01 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
EP2758072A1 (en) * 2011-09-23 2014-07-30 University Of Oslo Vaccibodies targeted to cross-presenting dendritic cells
WO2013154503A1 (en) * 2012-04-10 2013-10-17 Agency For Science, Technology And Research Methods for bladder cancer therapy using baculoviral vectors
ES2767050T3 (es) 2013-09-03 2020-06-16 Mayo Found Medical Education & Res Reducción del riesgo de eventos cardíacos adversos mayores
CN107207603A (zh) * 2015-02-03 2017-09-26 吉安特科技股份有限公司 趋化因子‑免疫球蛋白融合多肽，其组合物、制备方法以及用途
GB201603631D0 (en) * 2016-03-02 2016-04-13 Isis Innovation Therapy and diagnostics
KR20170123849A (ko) * 2016-04-29 2017-11-09 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
SG10201606949QA (en) * 2016-08-19 2018-03-28 Singapore Health Serv Pte Ltd Immunosuppressive composition for use in treating immunological disorders
EP3580230A1 (en) 2017-02-07 2019-12-18 VIB vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
US20200048321A1 (en) * 2017-03-24 2020-02-13 Orpheus Bioscience Inc. Pantids for treatment of autoimmune disorders
AU2018248672B2 (en) * 2017-04-05 2021-09-30 Korea Research Institute Of Bioscience And Biotechnology NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
CN109641032B (zh) * 2017-08-03 2022-06-24 泰加生物工艺学公司 用于治疗黑素瘤的方法和组合物
CN109422816B (zh) * 2017-08-25 2020-11-20 诺未科技（北京）有限公司 一种靶向次级淋巴组织的肝癌疫苗
US20190218285A1 (en) * 2018-01-18 2019-07-18 Molecular Cloning Laboratories (MCLAB) LLC Long-Acting Therapeutic Fusion Proteins
EA202190228A1 (ru) 2018-07-10 2021-04-14 Ридженерон Фармасьютикалз, Инк. Модификация связывающих молекул для минимизации уже существующих взаимодействий
US20220160753A1 (en) * 2019-03-27 2022-05-26 Immunophotonics, Inc. Semi-synthetic biopolymers for use in stimulating the immune system
CN114106207B (zh) * 2022-01-24 2022-04-26 诺未科技（北京）有限公司 Ccl5的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6723520B2 (en) * 1996-07-05 2004-04-20 Schering Corporation Antibodies that bind chemokine teck
US20070116669A1 (en) * 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
EP1440090A2 (en) 2001-10-23 2004-07-28 Centre for Translational Research in Cancer A synthetic chimeric fusion protein with immuno-therapeutic uses
AR046594A1 (es) * 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
WO2007021807A1 (en) * 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
WO2007148317A1 (en) * 2006-06-21 2007-12-27 Compugen Ltd. Mcp-1 splice variants and methods of using same
ES2456963T3 (es) * 2007-06-04 2014-04-24 Rappaport Family Institute For Research In The Medical Sciences Agentes para el tratamiento de enfermedades inflamatorias y métodos para usar los mismos
EP2205271B1 (en) * 2007-10-08 2014-05-21 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies

Also Published As

Publication number Publication date
WO2012166588A2 (en) 2012-12-06
CN108219001A (zh) 2018-06-29
US8541564B2 (en) 2013-09-24
CN103857406B (zh) 2018-02-23
US20130315909A1 (en) 2013-11-28
AU2012262491A1 (en) 2014-01-16
US20120308565A1 (en) 2012-12-06
US8987210B2 (en) 2015-03-24
CN103857406A (zh) 2014-06-11
EP2714065A2 (en) 2014-04-09
JP2014518632A (ja) 2014-08-07
EP2714065A4 (en) 2015-04-08
WO2012166588A3 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
HK1198126A1 (en) Chemokine immunoglobulin fusion polypeptides, compositions, method of making and use thereof
IL271870B (en) Factor viii chimeric and hybrid polypeptides and methods of using them
HK1247627A1 (zh) 多特異性fab融合蛋白及其使用方法
HK1208476A1 (en) Anti-b7-h6 antibody, fusion proteins, and methods of using the same b7-h6
EP2663647A4 (en) POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
HK1208827A1 (en) Interleukin-2 fusion proteins and uses thereof -2
EP2928924A4 (en) HIV-1 ENV BINDING ANTIBODIES, FUSION PROTEINS AND METHODS OF USE
EP2711377A4 (en) FUSION PROTEIN FOR ANTAGONIZING ANGIOGENICALLY INDUCIBLE FACTORS AND USE THEREOF
IL230209B (en) Serafin fusion polypeptides and methods of using them
EP2877854A4 (en) FUSION PROTEINS AND METHOD THEREFOR
EP2924049A4 (en) TROPHIC HORMONE FUSION PROTEIN, PREPARATION METHOD AND APPLICATION THEREOF
EP2773687A4 (en) FUSED THIOPHENES, PROCESSES FOR MAKING FUSED THIOPHENES AND USES THEREOF
EP2711376A4 (en) FGFR-FC FUSION PROTEIN AND USE THEREOF
HK1187369A1 (en) Fusion protein for secretory protein expression
EP2860181A4 (en) CONDENSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES OF SAID COMPOUND
EP2930189A4 (en) CHEMOKINE-CYTOKINE FUSION PROTEIN AND USE THEREOF
EP2744831A4 (en) TRANSFERRIN AND TUMSTANTINE-BASED FUSION PROTEIN AND METHODS OF PRODUCTION AND USE THEREOF
ZA201504817B (en) Hiv-1 env-binding antibodies, fusion proteins, and methods of use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220528